Prevalence of electronic nicotine delivery systems and electronic non-nicotine delivery systems in children and adolescents: a systematic review and meta-analysis.

Adolescent Child Electronic Nicotine Delivery Systems / statistics & numerical data Humans Prevalence

Journal

The Lancet. Public health
ISSN: 2468-2667
Titre abrégé: Lancet Public Health
Pays: England
ID NLM: 101699003

Informations de publication

Date de publication:
09 2021
Historique:
received: 22 01 2021
revised: 26 04 2021
accepted: 26 04 2021
pubmed: 19 7 2021
medline: 3 9 2021
entrez: 18 7 2021
Statut: ppublish

Résumé

There are concerns that the use of electronic nicotine delivery systems (ENDS) and electronic non-nicotine delivery systems (ENNDS) in children and adolescents could potentially be harmful to health. Understanding the extent of use of these devices is crucial to informing public health policy. We aimed to synthesise the prevalence of ENDS or ENNDS use in children and adolescents younger than 20 years. In this systematic review and meta-analysis, we undertook an electronic search in five databases (MEDLINE, Web of Science, Cumulative Index to Nursing and Allied Health Literature, Embase, and Wiley Cochrane Library) from Jan 1, 2016, to Aug 31, 2020, and a grey literature search. Included studies reported on the prevalence of ENDS or ENNDS use in nationally representative samples in populations younger than 20 years and collected data between the years 2016 and 2020. Studies were excluded if they were done in those aged 20 years or older, used data from specialist panels that did not apply appropriate weighting, or did not use methods that ensured recruitment of a nationally representative sample. We included the most recent data for each country. We combined multiple national estimates for a country if they were done in the same year. We undertook risk of bias assessment for all surveys included in the review using the Joanna Briggs Institute Critical Appraisal Checklist (by two reviewers in the author list). A random effects meta-analysis was used to pool overall prevalence estimates for ever, current, occasional, and daily use. This study was prospectively registered with PROSPERO, CRD42020199485. The most recent prevalence data from 26 national surveys representing 69 countries and territories, with a median sample size of 3925 (IQR 1=2266, IQR 3=10 593) children and adolescents was included. In children and adolescents aged between 8 years and younger than 20 years, the pooled prevalence for ever (defined as any lifetime use) ENDS or ENNDS use was 17·2% (95% CI 15-20, I There is significant variability in the prevalence of ENDS and ENNDS use in children and adolescents globally by country income status. These findings are possibly due to differences in regulatory context, market availability, and differences in surveillance systems. World Health Organization and the Bill & Melinda Gates Foundation.

Sections du résumé

BACKGROUND
There are concerns that the use of electronic nicotine delivery systems (ENDS) and electronic non-nicotine delivery systems (ENNDS) in children and adolescents could potentially be harmful to health. Understanding the extent of use of these devices is crucial to informing public health policy. We aimed to synthesise the prevalence of ENDS or ENNDS use in children and adolescents younger than 20 years.
METHODS
In this systematic review and meta-analysis, we undertook an electronic search in five databases (MEDLINE, Web of Science, Cumulative Index to Nursing and Allied Health Literature, Embase, and Wiley Cochrane Library) from Jan 1, 2016, to Aug 31, 2020, and a grey literature search. Included studies reported on the prevalence of ENDS or ENNDS use in nationally representative samples in populations younger than 20 years and collected data between the years 2016 and 2020. Studies were excluded if they were done in those aged 20 years or older, used data from specialist panels that did not apply appropriate weighting, or did not use methods that ensured recruitment of a nationally representative sample. We included the most recent data for each country. We combined multiple national estimates for a country if they were done in the same year. We undertook risk of bias assessment for all surveys included in the review using the Joanna Briggs Institute Critical Appraisal Checklist (by two reviewers in the author list). A random effects meta-analysis was used to pool overall prevalence estimates for ever, current, occasional, and daily use. This study was prospectively registered with PROSPERO, CRD42020199485.
FINDINGS
The most recent prevalence data from 26 national surveys representing 69 countries and territories, with a median sample size of 3925 (IQR 1=2266, IQR 3=10 593) children and adolescents was included. In children and adolescents aged between 8 years and younger than 20 years, the pooled prevalence for ever (defined as any lifetime use) ENDS or ENNDS use was 17·2% (95% CI 15-20, I
INTERPRETATION
There is significant variability in the prevalence of ENDS and ENNDS use in children and adolescents globally by country income status. These findings are possibly due to differences in regulatory context, market availability, and differences in surveillance systems.
FUNDING
World Health Organization and the Bill & Melinda Gates Foundation.

Identifiants

DOI: 10.1016/S2468-2667(21)00106-7 PMID: 34274048 PMC: PMC8390387
pubmed: 34274048
pii: S2468-2667(21)00106-7
doi: 10.1016/S2468-2667(21)00106-7
pmc: PMC8390387
pii:
doi:

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e661-e673

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests We declare no competing interests.

Références

Circulation. 2014 May 13;129(19):1972-86
pubmed: 24821826
Subst Abus. 2019;40(1):7-10
pubmed: 30883295
JAMA Netw Open. 2020 Dec 1;3(12):e2027465
pubmed: 33263760
BMJ Open. 2016 May 27;6(5):e011344
pubmed: 27235301
JAMA. 2019 Dec 3;322(21):2132-2134
pubmed: 31688891
Lancet. 2016 Dec 10;388(10062):e19-e23
pubmed: 27371184
Tob Control. 2016 Nov;25(Suppl 2):ii62-ii66
pubmed: 27633762
Tob Control. 2017 Jul;26(4):440-445
pubmed: 27903958
Nicotine Tob Res. 2019 Sep 19;21(10):1320-1330
pubmed: 29788314
JAMA. 2019 Dec 3;322(21):2095-2103
pubmed: 31688912
JAMA Intern Med. 2015 Oct;175(10):1671-80
pubmed: 26322924
Tob Control. 2020 Mar 10;:
pubmed: 32156694
BMJ. 2020 May 28;369:m1590
pubmed: 32467098
Tob Control. 2017 Aug 17;:
pubmed: 28818839
Addict Behav. 2019 Jun;93:93-99
pubmed: 30703668
Addiction. 2019 Jun;114(6):1060-1073
pubmed: 30681215
BMC Public Health. 2016 Apr 14;16:310
pubmed: 27075888
Drug Alcohol Depend. 2019 Aug 1;201:85-93
pubmed: 31200279
Curr Addict Rep. 2019 Jun;6(2):98-113
pubmed: 31453046
Open Med. 2009;3(3):e123-30
pubmed: 21603045
JAMA Pediatr. 2019 Oct 01;173(10):e192574
pubmed: 31403684
Lancet Public Health. 2020 Apr;5(4):e204-e212
pubmed: 31981489
Tob Control. 2017 Dec;26(e2):e85-e91
pubmed: 28003324
Nicotine Tob Res. 2019 Jan 1;21(1):14-24
pubmed: 29315420
Prev Med. 2020 Feb;131:105903
pubmed: 31812559
Cochrane Database Syst Rev. 2020 Oct 14;10:CD010216
pubmed: 33052602
Perspect Public Health. 2017 Nov;137(6):322-325
pubmed: 28379069
BMJ. 2019 Sep 30;366:l5275
pubmed: 31570493
Int J Evid Based Healthc. 2015 Sep;13(3):147-53
pubmed: 26317388
Front Public Health. 2018 Mar 26;6:86
pubmed: 29632856
J Adolesc Health. 2016 Dec;59(6):612-619
pubmed: 27693128
Prev Med. 2018 Nov;116:211-218
pubmed: 30261244
MMWR Morb Mortal Wkly Rep. 2018 Nov 16;67(45):1276-1277
pubmed: 30439875
Addiction. 2021 Apr;116(4):743-756
pubmed: 32888234
Aust N Z J Public Health. 2018 Jun;42(3):303-308
pubmed: 29528527
J Adolesc Health. 2017 Aug;61(2):155-162
pubmed: 28391965
Am J Drug Alcohol Abuse. 2020 Nov 1;46(6):684-698
pubmed: 32795246
Tob Prev Cessat. 2019 Apr 22;5:15
pubmed: 32411879
Prev Med Rep. 2016 Nov 11;5:33-40
pubmed: 27896041
MMWR Suppl. 2020 Aug 21;69(1):56-63
pubmed: 32817607
Can J Public Health. 2021 Feb;112(1):60-69
pubmed: 32804379

Auteurs

Sze Lin Yoong (SL)

School of Health Sciences, Swinburne University of Technology, Hawthorn, VIC, Australia; School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia; Priority Research Centre for Health Behaviour, University of Newcastle, Callaghan, NSW, Australia; Hunter Medical Research Institute, New Lambton Heights, NSW, Australia. Electronic address: syoong@swin.edu.au.

Alix Hall (A)

School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia; Priority Research Centre for Health Behaviour, University of Newcastle, Callaghan, NSW, Australia; Hunter Medical Research Institute, New Lambton Heights, NSW, Australia; Hunter New England Population Health, Wallsend, NSW, Australia.

Alecia Leonard (A)

School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia; Priority Research Centre for Health Behaviour, University of Newcastle, Callaghan, NSW, Australia.

Sam McCrabb (S)

School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia; Priority Research Centre for Health Behaviour, University of Newcastle, Callaghan, NSW, Australia; Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.

John Wiggers (J)

School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia; Priority Research Centre for Health Behaviour, University of Newcastle, Callaghan, NSW, Australia; Hunter Medical Research Institute, New Lambton Heights, NSW, Australia; Hunter New England Population Health, Wallsend, NSW, Australia.

Edouard Tursan d'Espaignet (E)

School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia; Priority Research Centre for Health Behaviour, University of Newcastle, Callaghan, NSW, Australia; Hunter New England Population Health, Wallsend, NSW, Australia; School of Rural Medicine, University of New England, Armidale, NSW, Australia.

Emily Stockings (E)

National Drug and Alcohol Research Centre, University of New South Wales, Randwick, NSW, Australia.

Hebe Gouda (H)

Department of Health Promotion, No Tobacco Unit, World Health Organization, Geneva, Switzerland.

Ranti Fayokun (R)

Department of Health Promotion, No Tobacco Unit, World Health Organization, Geneva, Switzerland.

Alison Commar (A)

Department of Health Promotion, No Tobacco Unit, World Health Organization, Geneva, Switzerland.

Vinayak M Prasad (VM)

Department of Health Promotion, No Tobacco Unit, World Health Organization, Geneva, Switzerland.

Christine Paul (C)

School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia; Priority Research Centre for Health Behaviour, University of Newcastle, Callaghan, NSW, Australia; Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.

Christopher Oldmeadow (C)

Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.

Li Kheng Chai (LK)

Health and Wellbeing Queensland, Queensland Government, Milton, QLD, Australia; Centre for Children's Health Research, Institute of Health and Biomedical Innovation Exercise and Nutrition, Queensland University of Technology, South Brisbane, QLD, Australia.

Bruce Thompson (B)

School of Health Sciences, Swinburne University of Technology, Hawthorn, VIC, Australia.

Luke Wolfenden (L)

School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia; Priority Research Centre for Health Behaviour, University of Newcastle, Callaghan, NSW, Australia; Hunter Medical Research Institute, New Lambton Heights, NSW, Australia; Hunter New England Population Health, Wallsend, NSW, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adolescent › Prevalence of electronic nicotine delivery...
questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › Prevalence of electronic nicotine delivery...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Dispositifs pour fumer › Dispositifs électroniques d'administration de nicotine › Prevalence of electronic nicotine delivery...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Prevalence of electronic nicotine delivery...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Prévalence › Prevalence of electronic nicotine delivery...